DUBLIN, Jan. 28, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today revealed its new direct-to-consumer campaign, "Own Your Look." The campaign, designed to address the most common misconceptions around BOTOX® Cosmetic (onabotulinumtoxinA), will encourage people to own their look and affirm their aesthetic choices.
BOTOX® Cosmetic is the most widely researched, studied and number one selling treatment of its kind and is the only product of its kind FDA-approved for three treatment areas – moderate to severe forehead lines, crow's feet and lines between the brows in adults.1-4 This is the first campaign from the brand created specifically to address millennial women and men who are increasingly curious about aesthetic treatments, while continuing to speak to the BOTOX® Cosmetic core consumer (women ages 34 – 45). According to the American Academy of Facial Plastic and Reconstructive Surgery's 2018 survey, the number of BOTOX® Cosmetic treatments among 22 to 37-year-olds has risen by 22% since 2013.5
"As the category leader who created this market, it's our job to continue to educate consumers about their aesthetic choices. Millennial consumers are curious about BOTOX® Cosmetic, and this new campaign will modernize the iconic brand to appeal to this generation and empower them to own their look with BOTOX® Cosmetic," says Carrie Strom, Senior Vice President, U.S. Medical Aesthetics. "We know there are 25 million people currently considering injectable treatments in the U.S. today,6 and the most common reason preventing them from getting treated is the fear of looking unnatural. The 'Own Your Look' campaign addresses this head-on, by showcasing real BOTOX® Cosmetic users in their 20s, 30s, and 40s and their authentic facial expressions in response to all sorts of life events. Our goal is to let consumers know that BOTOX® Cosmetic delivers subtle results – so they can look like themselves, just with fewer lines."1
Allergan owns the entire BOTOX® Cosmetic manufacturing process and every vial is made exclusively in a state-of-the-art facility in Westport, Ireland, which adheres to strict quality and safety standards. BOTOX® Cosmetic is a unique product; no other product is exactly the same.
Visit BotoxCosmetic.com for more information about BOTOX® Cosmetic or to find a doctor. Follow BOTOX® Cosmetic on Instagram® @BotoxCosmetic.
BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.
IMPORTANT SAFETY INFORMATION
BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:
Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.
BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.
BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® Cosmetic. If this happens, do not drive a car, operate machinery, or do other dangerous activities.
Serious and/or immediate allergic reactions have been reported. They include: itching, rash, red itchy welts, wheezing, asthma symptoms, or dizziness or feeling faint. Get medical help right away if you are wheezing or have asthma symptoms, or if you become dizzy or faint.
Do not receive BOTOX® Cosmetic if you: are allergic to any of the ingredients in BOTOX® Cosmetic (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.
Tell your doctor about all your muscle or nerve conditions, such as ALS or Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® Cosmetic.
Tell your doctor about all your medical conditions, including: plans to have surgery; had surgery on your face; have trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; are pregnant or plan to become pregnant (it is not known if BOTOX® Cosmetic can harm your unborn baby); are breast-feeding or plan to (it is not known if BOTOX® Cosmetic passes into breast milk).
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using BOTOX® Cosmetic with certain other medicines may cause serious side effects. Do not start any new medicines until you have told your doctor that you have received BOTOX® Cosmetic in the past.
Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.
Other side effects of BOTOX® Cosmetic include: dry mouth; discomfort or pain at the injection site; tiredness; headache; neck pain; and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids and eyebrows, swelling of your eyelids and dry eyes.
For more information refer to the Medication Guide or talk with your doctor.
To report a side effect, please call Allergan at 1-800-678-1605.
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical leader. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.
Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.
With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2017 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2018. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
1. BOTOX® Cosmetic Prescribing Information, 2017.
2. Data on File, Allergan; Patient Clinicals, 2015.
3. Data on File, Allergan; Peer-Reviewed Articles, 2018.
4. Data on File, Allergan; BOTOX® Cosmetic 2015 WW Leader in Cosmetic NM Market, 2018.
5. American Academy of Facial Plastic and Reconstructive Surgery; Annual Survey Results, 2018.
6. Data on File, Allergan; Allergan Highlights Key Growth Drivers for Medical Aesthetics. Google Analytics, 2018.